A Single-center, Randomized, Double-blind, Placebo-controlled, Multiple Dose Escalating Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of PB-119 Injection in Chinese Obese Subjects
Latest Information Update: 17 Jun 2024
At a glance
- Drugs Pegylated exenatide (Primary)
- Indications Obesity
- Focus Adverse reactions
- Sponsors PegBio
Most Recent Events
- 11 Jun 2024 Status changed from recruiting to active, no longer recruiting.
- 28 May 2024 Status changed from not yet recruiting to recruiting.
- 08 Apr 2024 New trial record